TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Opyl Ltd. ( (AU:PKY) ) has shared an announcement.
Pathkey.AI Ltd has made significant strides in the September 2025 quarter, transitioning from validation to commercial scale. The company has validated the predictive performance of its TrialKey platform, which accurately forecasts clinical trial outcomes and share price inflection points. Enhancements in AI capabilities have expanded the platform’s application towards drug discovery and compound repurposing. Strategic partnerships have been strengthened, and new leadership appointments have been made to guide the company’s growth. Financial discipline has been maintained, with treasury assets and director-supported funding initiatives providing additional flexibility.
More about Opyl Ltd.
Pathkey.AI Ltd (ASX: PKY) is a leader in AI-driven clinical trial optimization, focusing on applying artificial intelligence to enhance clinical trial design, predict trial outcomes, and support data-driven drug development.
Average Trading Volume: 1,086,317
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$6.05M
See more data about PKY stock on TipRanks’ Stock Analysis page.